Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 278

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 278
---
 they may not otherwise provide us with a competitive advantage.
Our competitors, or other third parties, may be able to circumvent our patents by developing similar or alternative technologies
or products in a non-infringing manner. For example, there is no assurance that the CC8464 Patent, or any other patent that we
may be granted, will prevent third parties from developing competing technologies. Moreover, our patent estate, including the
CC8464 Patent, does not preclude third parties from obtaining intellectual property rights that could interfere with our freedom
to use our platform for other indications. Even assuming patents issue from our pending and future patent applications, changes
in either the patent laws or interpretation of the patent laws in the United States and foreign jurisdictions may diminish the
value of our patents or narrow their scope of protection.

We
have pending patent applications for both of CT2000 and CT3000 and there is no guarantee that any of these applications become
patents in the United States or any other jurisdiction.

We
may not be able to protect our intellectual property or enforce our intellectual property rights adequately throughout the world.

Filing
and prosecuting patent applications on CC8464, CT2000, CT3000 and future new compounds, current and future innovations related
to our technology, and our institutional knowledge in all countries throughout the world would be prohibitively expensive, and
intellectual property protections available in some countries outside the United States, and the enforceability thereof, may differ
in scope from those in the United States. Thus, in some cases, we will not seek to obtain patent protection for certain technologies
in some jurisdictions outside the United States. In addition, the laws of some foreign countries do not protect intellectual property
to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from
utilizing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection.
Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their
own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement
is not as strong as that in the United States. These products may compete with our compounds, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing.

Many
companies have encountered significant problems in protecting intellectual property and enforcing intellectual property rights
in foreign jurisdictions. The legal systems of certain countries, particularly